Drug intelligence / Profile preview

IM73 CAR-T cells

Development stage: Phase 1
Lead developer: Immunochina Pharmaceuticals
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

IM73 CAR-T cells are a donor-derived chimeric antigen receptor (CAR) T-cell therapy developed by Beijing Immunochina Medical Science & Technology Co., Ltd. This cell therapy is being investigated for the treatment of patients with relapsed or refractory acute myeloid leukemia. CAR-T cell therapy involves genetically engineering T cells to express a synthetic receptor that enables them to recognize and target specific antigens on cancer cells, leading to their destruction.

Other names: Donor-derived CAR-T cells

Beyond the preview

Go deeper on IM73 CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IM73 CAR-T cells.

Explore the full profile